In a phase II trial of ANGPTL3 inhibition involving 9 patients with homozygous familial hypercholesterolemia, evinacumab treatment resulted in a mean reduction from baseline of 49% in the LDL-C level. This evidence concerns the gene ANGPTL3 and familial hypercholesterolemia.